Special Issue

Personalized Medicine in Ear, Nose, Throat, Head and Neck Surgery

Message from the Guest Editor

The Journal of Personlized Medicine will be posting a Special Issue entitled "Personalized Medicine in Ear, Nose, Throat, Head and Neck Surgery", focusing on the unique aspects of our field in the unique settings and subsites of otolaryngology. We aim to present breakthroughs in the fields of subtyping of the different diseases, oncological treatments tailored to genomic data, novel classifications of known pathologies, and implementations of novel techlogoies to unique and challenging cases. We also aim to demonstrate cutting edge AI tools and computational data studies, and their relevance in the personalization of medical cases in the field of otolaryngology. We are looking forward to hear from you.

Guest Editor

Dr. Narin Nard Carmel-Neiderman

Sinus Surgery Unit, The Department of Otolaryngology Head and Neck and Maxillofacial Surgery & Head and Neck Cancer Research Laboratory, Tel-Aviv Sourasky Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel

Deadline for manuscript submissions

28 February 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/207332

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

